Tavapadon, a drug being tested to treat early Parkinson's disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week. Parkinson’s disease ...

US-based pharmaceutical company AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon, its D1/D5 partial agonist candidate for early-stage Parkinson's disease, met its primary endpoint.

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

The company recently announced the successful completion of a third "late-stage" clinical trial for tavapadon, a Parkinson's disease medication. That successful test will allow AbbVie to seek the ...

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II ...

On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...

treatment with tavapadon as a monotherapy in adults with early Parkinson's disease. The trial met its primary endpoint – patients treated with tavapadon experienced a statistically significant ...